Proteome Systems is a biotechnology company that specializes in the discovery of biomarkers of disease and in diagnostic test development. Proteome Systems focuses on the commercialization of its intellectual property for the discovery of biomarkers and develops diagnostic tests, based on its proprietary test platform DiagnostIQ™. The discovery program is based on the company’s integrated proteomics technology platform ProteomlQ™ and web-based proteomics information management system BioinformatlQ™. The company’s discovery and development programs include reproductive cancers, infectious diseases, neurodegenerative diseases and respiratory diseases such as tuberculosis, prostate cancer and Huntington’s disease. Biomarkers are validated through the Proteome Systems’ technology pipeline for potential use in diagnostic and prognostic tests for use in monitoring the effectiveness of drug treatments or as surrogate markers in clinical trials.